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OBJECTIVE — Weight loss in type 2 diabetes is undisputedly important, and data from
community settings are limited. We evaluated weight change and resulting glycemic and blood
pressure control in type 2 diabetic patients at an HMO.
RESEARCH DESIGN AND METHODS — Using electronic medical records, this ret-
rospectivecohortstudyidentiﬁed2,574patientsaged21–75yearswhoreceivedanewdiagnosis
oftype2diabetesbetween1997and2002.Weestimated3-yearweighttrajectoriesusinggrowth
curveanalyses,groupedsimilartrajectoriesintofourcategoriesusingclusteranalysis,compared
category characteristics, and predicted year-4 above-goal A1C and blood pressure by group.
RESULTS — The weight-trajectory groups were deﬁned as higher stable weight (n  418;
16.2%),lowerstableweight(n1,542;59.9%),weightgain(n300;11.7%),andweightloss
(n  314; 12.2%). The latter had a mean weight loss of 10.7 kg (9.8%; P  0.001) by 18
months, with near-complete regain by 36 months. After adjusting for age, sex, baseline control,
and related medication use, those with higher stable weight, lower stable weight, or weight-gain
patterns were more likely than those who lost weight to have above-goal A1C (odds ratio [OR]
1.66 [95% CI 1.12–2.47], 1.52 [1.08–2.14], and 1.77 [1.15–2.72], respectively). Those with
higherstableweightorweight-gainpatternsweremorelikelythanthosewholostweighttohave
above-goal blood pressure (1.83 [1.31–2.57] and 1.47 [1.03–2.10], respectively).
CONCLUSIONS — A weight-loss pattern after new diagnosis of type 2 diabetes predicted
improved glycemic and blood pressure control despite weight regain. The initial period postdi-
agnosis may be a critical time to apply weight-loss treatments to improve risk factor control.
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A
lmost all adults with diabetes are
overweight; more than half are
obese (1). Obesity is associated
with worse blood glucose and other car-
diovascularriskfactorcontrol(2).Results
from the Look AHEAD trial show that
weightlossindiabetesimprovesglycemic
control, reduces blood pressure, and im-
proves blood lipids (3). Observational
studies also support a likely link between
weight loss and reduced mortality in peo-
ple with diabetes (2).
Limited data describe the extent to
whichweightloss,aswellasresultinglev-
els of glycemic and blood pressure con-
trol, is achieved in community-living
people with type 2 diabetes (4,5). Most
weight information on these subjects
comes from research volunteers (4,5).
Prior studies of health effects of weight
change have been plagued by confound-
ing of low weight by disease burden and
by difﬁculty separating intentional from
unintentional weight loss (6,7).
This study used electronic medical
records data to evaluate weight trajecto-
ries in the initial years following a new
type 2 diabetes diagnosis, associated de-
mographic and comorbidity factors, and
resulting glycemic and blood pressure
control. The initial period after a diabetes
diagnosis is of particular interest because
this may be a time of heightened patient
and clinician interest in patient behavior
change (8).
RESEARCH DESIGN AND
METHODS—The study design and
procedures were approved by the study
site’s institutional review board.
Study site and data sources
The study was conducted at Kaiser Per-
manente Northwest (KPNW), a not-for-
proﬁt HMO in the Paciﬁc Northwest with
480,000 members. Electronic medical
records include patient weight, blood
pressure, height, smoking status, diag-
noses, treatment procedures, medica-
tions, and laboratory results. The KPNW
diabetes registry has been shown to be
99.5% speciﬁc and 99% sensitive for dia-
betes diagnosis compared with chart re-
view (9). KPNW members with diabetes
aredemographicallyandclinicallysimilar
tothenationalpopulationofpatientswith
diabetes (9).
The study site’s clinical guidelines for
diabetes care are consistent with prevail-
ing guidelines (10). Guidelines recom-
mend lifestyle management for all people
with diabetes and a stepped-care ap-
proach to medication use for control of
risk factors. Most newly diagnosed mem-
bers attend diabetes classes, and HMO
weight-related health-education classes
are available for a fee.
Study design and identiﬁcation of
participants
This retrospective cohort study evalu-
ated3-yearweighttrajectorypatternsin
subjects aged 21–75 years and newly
diagnosed with type 2 diabetes, as well
as the patterns’ effects on A1C and
blood pressure in year 4. We identiﬁed
all men and women aged 21–75 years
with any evidence of type 2 diabetes
(n  38,430). We then limited the pop-
ulation to those with newly diagnosed
type 2 diabetes from 1 January 1997 to
31 December 2002 (n  17,403) and
then further limited it to those with 12
months’ pre- and 36 months’ postdiag-
nosis continuous HMO membership
(n  8,540). A diabetes diagnosis was
assigned to those who met diabetes reg-
istry criteria: documentation of an inpa-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and
2Northwest
Permanente, Portland, Oregon.
Corresponding author: Adrianne C. Feldstein, adrianne.c.feldstein@kpchr.org.
Received 28 February 2008 and accepted 14 June 2008.
Published ahead of print at http://care.diabetesjournals.org on 12 August 2008. DOI: 10.2337/dc08-0426
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
1960 DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008tient or outpatient type 2 diabetes
diagnosis, fasting plasma glucose 125
mg/dl, or diabetes medication dis-
pensed. The ﬁrst diagnosis date served
as the index date. A diagnosis was con-
sidered new if the patient had not met
the qualifying criteria in the 12 months
before diabetes registry entry. We ex-
cluded 3,833 patients with a severe ill-
ness or condition associated with
unintentional weight change in the 12
months preperiod or during trajectory:
69.0% (n  2,645) with cancer, 12.0%
(n  460) on home oxygen, 5.0% (n 
191) with a pregnancy, 5.0% (n  193)
with amputation(s), and 9.0% (n 
344) with any of the following condi-
tions: HIV, nutritional deﬁciency, bari-
atric surgery, dialysis, hospice, or care
facility stay 30 days and BMI 20
kg/m
2 (n  4,707 remained). Finally,
we included only those with a weight
measurement at baseline and at least
ﬁve weight measurements in the 3 years
postdiagnosis (to explore differently
shaped weight-change curves); the ﬁnal
weight measurement had to occur 30 to
36 months postindex (ﬁnal n  2,574
patients). Those excluded as a result of
weight requirements were younger
(54.5 vs. 56.3 years; P  0.001) and
more likely to be male (52.3 vs. 47.3%;
P  0.001) and have a higher A1C
(8.2 vs. 8.0%; P  0.023), but they did
not have signiﬁcantly different blood
pressure.
Study variables
The primary outcomes were above-goal
A1C (7%) and above-goal blood pres-
sure (130/80 mmHg) (10) during the
4th year after the index date, using mean
values.ToadjustforbaselineA1C,wede-
ﬁned baseline as A1C measures that were
taken during year 1 because few partici-
pants had pre–diabetes diagnosis A1C
measures.Additionalanalysesconsidered
only patients with A1C measured in a
3-month window around the index date.
Baseline blood pressure (above goal) was
based on mean blood pressure in the 12
months before index.
We used all weight measurements to
createa3-yeartrajectoryforeachindivid-
ual. Baseline was deﬁned as the preperiod
measurement of weight closest to the in-
dex date. The 3-year weight was the mea-
surecollectedclosesttotheendofthe30-
to 36-month interval.
We included a group of covariates
traditionally associated with weight or
weight change (11–13): age at index date
(11),sex(12),whethertheindividualwas
inagroupat“race-risk”forobesity(Black,
Hispanic,NativeAmerican,andPaciﬁcIs-
lander, combined) (12), Medicaid enroll-
ment, and family income $40,000 per
year (11). Race data were available for
77% of patients. To approximate missing
race data and to assign family income, we
used participants’ mailing addresses to
obtain census tract block data.
We used baseline weight and any
available height to determine baseline
BMI and obesity (BMI 30 kg/m
2) status
(1).Currentsmokingwasnotedusingthe
preperiodrecordclosesttotheindexdate.
We used the mean number of unique
medications dispensed in the prediagno-
sis period as a measure of disease burden
(14). We noted baseline diagnoses that
could affect or be affected by weight or
weight change: hypertension, dyslipide-
mia, cardiovascular disease (excluding
congestive heart failure), microvascular
disease(retinopathy,neuropathy,andne-
phropathy, combined), depression, and
conditions that could interfere with activ-
ity (asthma, chronic obstructive pulmo-
nary disease, and arthritis, combined)
(13).
We used the following diabetes med-
ication categories for any single medica-
tion dispensed for 30 days during year
4: “sulfonylureas” for patients dispensed
sulfonylureas (but not metformin), “met-
formin” for those dispensed metformin
(but not sulfonylureas), “sulfonylureas
andmetformin”forthosedispensedboth,
thiazolidinedione, acarbose, and repa-
glinide. Insulin use was indicated for
those to whom any insulin was dispensed
during year 4. We used the blood pres-
sure medication categories beta blocker,
diuretic, ACE inhibitor, angiotensin re-
ceptor blocker, or “other antihyperten-
sive” medication for those dispensed for
30 days during year 4.
Statistical analysis
Individual weight trajectories were esti-
mated using growth curve analyses (mul-
tilevel modeling) with HLM 6.0. Time
formed the ﬁrst level of the model, with
weight as the dependent variable. We
used both linear and quadratic models to
determine best ﬁt for the data. The inter-
cept and slope parameters describing in-
dividual weight trajectories were entered
into a hierarchical cluster analysis, using
Figure1—Thefourdominantweight-changetrajectorypatternsinthethreeyearsafterdiagnosis
of type 2 diabetes. F, group with higher stable weight (n  418; 16.2%); ‚, weight-loss group (n
 314; 12.2%); Œ, weight-gain group (n  300; 11.7%); f, group with lower stable weight (n 
1,542; 59.9%); and %‚, percentage weight change from baseline. **Estimated baseline weights
differfrommeanbaselineweightsinTable1.*Percentageweightchanges(month0–month18and
month 0–month 36) are signiﬁcantly different from zero (P  0.001 based on Wilcoxon’s signed-
rank test).
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groupsofpatientswithsimilarweighttra-
jectories.WeusedANOVAand
2teststo
compare characteristics of groups. Mul-
tiple logistic regression models estimated
the unadjusted effect of membership in a
weight-trajectory cluster on above-goal
A1Candbloodpressureinyear4,aswellas
the effect while controlling for factors that
were statistically signiﬁcant in univariate
analyses and are known to affect glycemic
and blood pressure control (3). Adjusted
modelonecontrolledforage,sex,andbase-
line A1C or blood pressure control, and
model two added diabetes or blood pres-
sure medication use at year 4. The weight
loss–trajectory cluster was the reference
group. We considered P  0.05 to be sta-
tistically signiﬁcant.
RESULTS—When estimating weight
trajectories, we found that the quadratic
model ﬁt signiﬁcantly better than the lin-
ear model (P  0.0001). Therefore, three
variables representing an individual’s
weight trajectory were included in the
cluster analysis: intercept (estimated
baseline weight), linear slope, and qua-
dratic slope.
We found four weight-trajectory
clusters (Figure 1). The group with a
higher stable weight (n  418; 16.2%)
and the group with a lower stable weight
(n  1,542; 59.9%) largely maintained
their weights. The weight-gain group
(n  300; 11.7%) began at a mean weight
of107.8kgandgainedweightuntilabout
18 months, reaching a mean of 114.7 kg
(6.4% gain; P  0.001), followed by a
weightloss;endingmeanweightwasnear
baseline.Theweight-lossgroup(n314;
12.2%) began at a mean weight of 109.3
kgandlostweightuntilabout18months,
reaching a mean of 98.6 kg (9.8% loss),
followed by a regain to approximately
baseline weight. Notably, the weight-gain
and weight-loss groups began and ended
at similar mean weights.
Table 1 compares baseline characteris-
tics of the study subjects. The four groups
were signiﬁcantly different with respect to
age, sex, baseline weight and BMI, race, di-
agnosed depression, and hypertension and
blood pressure. Of note is that the mean
baseline(year1)A1Candthepercentabove
goal were signiﬁcantly different across
groups and lower in the weight-loss com-
pared with the weight-gain group.
Table 1—Baseline characteristics of patients with new-onset type 2 diabetes by weight change–trajectory pattern
Higher stable
weight
Lower stable
weight Weight loss Weight gain P*
n (%) 418 (16.2) 1,542 (59.9) 314 (12.2) 300 (11.7)
Age (years) 52.9  8.9 57.7  10.3 55.9  9.7 54.4  9.9 0.001†
Female sex 174 (41.6) 876 (56.8) 165 (52.6) 141 (47.0) 0.001
Weight (kg) 129.4  17.7 89.0  15.0 111.0  20.5 108.0  20.0 0.001
BMI (kg/m
2) 43.1  7.0 32.3  5.2 38.9  7.2 37.0  7.0 0.001†
BMI category (kg/m
2) 0.001†
25 0 (0.0) 97 (6.3) 1 (0.3) 7 (2.3)
25 to 30 2 (0.5) 452 (29.3) 19 (6.1) 43 (14.3)
30 to 40 147 (35.1) 869 (56.4) 170 (54.1) 157 (52.3)
40 269 (64.4) 124 (8.0) 124 (39.5) 93 (31.0)
Race risk‡ 16 (3.8) 112 (7.3) 12 (3.8) 15 (5.0) 0.012
Family income $40,000/year 83 (19.9) 293 (19.0) 47 (15.0) 64 (21.3) 0.205†
Medicaid 17 (4.1) 68 (4.4) 10 (3.2) 15 (5.0) 0.703
Current smoker 61 (14.6) 254 (16.5) 53 (16.9) 65 (21.7) 0.084
No. of medications 7.5  5.8 7.7  5.7 7.9  6.0 8.3  6.0 0.241
Median (IQR) 6.5 (3–10) 7 (3–11) 7 (4–11) 7 (4–11.5)
Depression 61 (14.6) 183 (11.9) 45 (14.3) 53 (17.7) 0.035
Hypertension 237 (56.7) 704 (45.7) 163 (51.9) 137 (45.7) 0.001
Dyslipidemia 89 (21.3) 405 (26.3) 73 (23.3) 67 (22.3) 0.116
CVD (excluding CHF) 43 (10.3) 183 (11.9) 30 (9.6) 39 (13.0) 0.450
Microvascular disease§ 40 (9.6) 114 (7.4) 25 (8.0) 22 (7.3) 0.517
Asthma/COPD/arthritis¶ 126 (30.1) 393 (25.5) 80 (25.5) 89 (29.7) 0.153
A1C (year 1)¶ 7.2  1.1 7.1  1.2 6.7  1.0 7.3  1.3 0.001†
Median (IQR) 6.9 (6.3–7.8) 6.8 (6.3–7.6) 6.5 (6.0–7.3) 6.9 (6.4–8.0)
A1C above goal 178 (47.7) 591 (43.6) 97 (33.9) 123 (46.6) 0.001†
Systolic blood pressure# 140.1  13.6 137.6  15.1 138.3  13.8 137.2  15.7 0.002
Median (IQR) 139 (132–147) 136 (127–147) 138 (128–147) 136 (127–147)
Diastolic blood pressure# 85.9  8.1 82.3  8.0 83.9  7.9 84.1  9.2 0.001
Median (IQR) 86 (80–91) 82 (77–87) 84 (79–89) 84 (79–89)
Blood pressure above goal 369 (88.3) 1211 (78.5) 257 (81.9) 237 (79.3) 0.001
Data are means  SD or n (%) unless otherwise indicated. *Comparison across all four groups. †Comparison of weight-gain and weight-loss groups signiﬁcant at
P0.05.‡Deﬁnedasanyofthefollowing:AfricanAmerican/Hispanic/AmericanIndian/PaciﬁcIslander.¶Combinednoncardiovasculardiagnosesthatmayinterfere
with activity. §Retinopathy, neuropathy, and nephropathy grouped together.  A1C means based on 373 subjects (89.2%) in higher-stable, 1,355 (87.9%) in
lower-stable, 286 (91.1%) in weight-loss, and 264 (88.0%) in weight-gain groups that had one or more measures during year 1. #Blood pressure means based on
418 subjects (100%) in higher-stable, 1,542 (100%) in lower-stable, 314 (100%) in weight-loss, and 299 (99.7%) in weight-gain groups that had one or more
measures during the baseline year. CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IQR, interquartile
range.
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A1C and blood pressure results in year 4
by group. The weight-loss group had the
lowest percentage of individuals with
above-goal A1C (by year 4, the difference
between it and other groups had become
more prominent) and blood pressure and
more favorable means and distributions
of both measures. Metformin use in the
weight-loss group remained stable (19.4%
inyear1vs.23.6%inyear4),whereasuse
in the weight-gain group increased from
18.3% in year 1 to 41.3% in year 4 (data
not shown).
Table 3 presents the logistic regres-
sion models comparing above-goal A1C
in year 4 in the three other weight-
change trajectories with that in the
weight-loss group (limited to the 1,911
[74.2%] patients who had one or more
A1C measures in both years 1 and 4). In
the three models, the likelihood of
above-goal A1C remained signiﬁcantly
higher among the groups with higher
stable weight, lower stable weight, and
weight gain than in the weight-loss
group. The magnitude of the effect is
diminished by adding the covariates.
In the fully adjusted model 2, those
with higher stable weight were 1.7 times
more likely (95% CI 1.1–2.5) to have
above-goal A1C than those in the weight-
lossgroup,thosewithlowerstableweight
were 1.5 times more likely (1.1–2.1), and
those with weight gain were 1.8 times
more likely (1.2–2.7). Each year of age
reduced the odds of above-goal A1C by
3% (odds ration [OR] 0.97 [95% CI
0.96–0.98]). Those with above-goal A1C
at year 1 were 2.4 times more likely to be
above goal at year 4 (95% CI 2.7–4.0).
When analyses were restricted to
1,599 patients with a true baseline A1C
measure, the odds of above-goal A1C in
year 4 were 2.3 (95% CI 1.4–3.7) times
higher in the weight-gain group than in
the weight-loss group. Also, baseline BMI
alone (vs. trajectory membership) did not
signiﬁcantly predict above-goal A1C in
year 4 (data not shown).
Table 3 also presents logistic regression
models comparing above-goal blood pres-
sure in year 4 in the other weight-change
trajectories to blood pressure in the weight-
loss group (limited to the 2,410 [93.6%]
patients who had one or more blood pres-
sure measures in year 4). In the fully ad-
justed model 2, those with higher stable
weight were 1.8 times more likely (95% CI
1.3–2.6) than those in the weight-loss
group to have above-goal blood pressure,
and those with weight gain were 1.5 times
more likely (1.1–2.1). Each year of age in-
creased the odds of being above goal by 2%
(OR1.02[95%CI1.01–1.03]).Thosewith
above-goal blood pressure at year 1 were
2.9 times more likely to be above goal at
year 4 (95% CI 2.4–3.6).
CONCLUSIONS —We found that
12.2% of people with type 2 diabetes in
ourpopulationhadamean3-yearweight-
change trajectory that included a clini-
cally signiﬁcant (9.8% at 18 months) (2)
mean weight loss. Despite weight regain
during the 3-year period, those who ini-
tially lost weight had improved glycemic
andbloodpressurecontrolinyear4com-
Table 2—Glycemic and blood pressure in year 4 by 3-year weight change–trajectory pattern
Higher stable
weight
Lower stable
weight Weight loss Weight gain P*
A1C measurements
n (%) 322 (16.9) 1,135 (59.4) 227 (11.9) 227 (11.9)
Above-goal mean A1C (%)† 153 (47.5) 472 (41.6) 63 (27.8) 118 (52.0) 0.0001
A1C (%) 7.2  1.3
c 7.0  1.2
ad 6.6  1.1
bcd 7.3  1.4
ab 0.0001
Median (IQR) 6.9 (6.3–7.8) 6.8 (6.2–7.5) 6.4 (5.8–7.1) 7.0 (6.2–78.0)
Mean A1C stratum (%) 0.0001
7 169 (52.5) 663 (58.4) 164 (72.2) 109 (48.0)
7–8 87 (27.0) 277 (24.4) 41 (18.1) 59 (26.0)
8–9 37 (11.5) 120 (10.6) 14 (6.2) 31 (13.7)
9 29 (9.0) 75 (6.6) 8 (3.5) 28 (12.3)
Blood pressure measurements
n (%) 396 (16.4) 1447 (60.1) 285 (11.8) 281 (11.7)
Above-goal mean blood pressure (mmHg)† 291 (73.5) 893 (61.7) 172 (60.4) 189 (67.3) 0.0001
Systolic blood pressure (mmHg) 135.9  12.9
ab 132.9  14.0
a 131.6  13.2
b 133.4  13.3 0.0001
Median (IQR) 135 (127–144) 132 (123–141) 131 (122–139) 132 (125–140)
Diastolic blood pressure (mmHg) 80.1  7.8
ab 77.1  8.2
bd 77.4  8.4
ac 79.3  8.3
cd 0.0001
Median (IQR) 80 (75–85) 77 (71–82) 79 (72–82) 80 (74–84)
Mean systolic blood pressure stratum (mmHg) 0.0364
130 143 (36.1) 650 (44.9) 135 (47.4) 133 (47.3)
130–139 110 (27.8) 389 (26.9) 81 (28.4) 69 (24.6)
140–159 125 (31.6) 355 (24.5) 61 (21.4) 69 (24.6)
160 18 (4.5) 53 (3.7) 8 (2.8) 10 (3.5)
Mean diastolic blood pressure stratum (mmHg) 0.0001
80 198 (50.0) 970 (67.0) 182 (63.9) 151 (53.7)
80–89 155 (39.1) 385 (26.6) 82 (28.8) 104 (37.0)
90–99 40 (10.1) 84 (5.8) 19 (6.6) 24 (8.6)
100 3 (0.8) 8 (0.6) 2 (0.7) 2 (0.7)
Data are n (%) and means  SD unless otherwise indicated. *Comparison across all 4 groups. †Includes those with one or more measures during year 4.
abcdMeans
with the same superscripts are signiﬁcantly different from one another at P  0.05. IQR, interquartile range.
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weight-gain trajectories. These ﬁndings
suggest that, even in the face of weight
regain (15), losing weight can have long-
lasting beneﬁts in type 2 diabetes. The
therapeutic advantage achieved through
weight loss is exceedingly important
given the close connection between gly-
cemic and blood pressure control (espe-
cially in the ﬁrst years postdiagnosis) and
cardiovascular outcomes (16,17).
Although helping patients achieve
weight loss can be overwhelming (18),
physicians can feel encouraged by the
weight trajectories we observed in free-
living people with type 2 diabetes during
the 3 years after initial diagnosis. Some
people achieved weight loss despite the
fact that the study site, similar to many
communities (18), directs fewer re-
sources to weight loss than to monitoring
and medications. Practitioners frustrated
by the frequency of weight regain (15)
may be reinvigorated by our ﬁnding that
weight regain in diabetes may not imply
lackoftherapeuticbeneﬁtsofweightloss.
The weight-loss group, on average,
began regaining at about 18 months. This
suggeststhattheﬁrstmonthspostdiagno-
sis may provide a window to capitalize on
patient and clinician motivation by ac-
tively applying weight-loss interventions.
However, additional support for main-
taining weight loss will be important.
Recent ﬁndings from the Look AHEAD
weightlossindiabetesstudyrevealedthat
the intensive lifestyle intervention group
lost, on average, 8.6% of their initial
weight at 1 year, compared with 0.7% in
the education control group (3). The
magnitude of weight change noted in our
community weight-losing cohort was
similar. At year 4, the absolute A1C and
blood pressure differences between those
who lost or gained weight were small but
similar to differences observed between
intervention and control subjects in Look
AHEAD(3).TheA1Ceffectsseenhereare
clinically signiﬁcant: prior studies have
concludedthateverypercentagepointre-
duction in mean A1C correlates with a
37% reduction in risk of microvascular
complications and a 21% reduction in
risk of any diabetes-related end point and
diabetes-related deaths. No threshold has
beenobservedfortheserisks(19).Riskof
death from ischemic heart disease and
stroke also increases progressively and
linearly starting from blood pressure lev-
els as low as 115/75 mmHg (20).
Last, our models controlling for med-
ication use in year 4 may have provided
conservative estimates of effects of weight
Table 3—Impact of 3-year weight change–trajectory pattern and covariates on above-goal A1C* and blood pressure† at year 4
Unadjusted model Adjusted model 1 Adjusted model 2
OR 95% CI P OR 95% CI P OR 95% CI P
A1C outcome
Weight trajectory clusters
Higher stable weight 2.36 1.64–3.39 0.0001 1.96 1.34–2.87 0.0006 1.66 1.12–2.47 0.0118
Lower stable weight 1.85 1.35–2.53 0.0001 1.83 1.32–2.55 0.0003 1.52 1.08–2.14 0.0158
Weight gain 2.82 1.91–4.16 0.0001 2.59 1.72–3.91 0.0001 1.77 1.15–2.72 0.0094
Weight loss 1.00 — — 1.00 — — 1.00 — —
Age (years) 0.97 0.96–0.98 0.0001 0.97 0.96–0.98 0.0001
Male sex 1.02 0.84–1.24 0.861 1.07 0.87–1.31 0.541
A1C above goal (year 1) 3.35 2.76–4.07 0.0001 2.42 1.97–2.98 0.0001
Oral hyperglycemic medication class year
4‡
Metformin 1.54 1.14–2.08 0.0047
Sulfonylureas 2.16 1.67–2.81 0.0001
Metformin and sulfonylureas 4.40 3.30–5.86 0.0001
Neither sulfonylureas nor metformin 1.00 — —
Insulin 2.25 1.41–3.59 0.0006
Blood pressure outcome
Weight-trajectory clusters
Higher stable weight 1.82 1.31–2.52 0.0003 1.84 1.32–2.58 0.0004 1.83 1.31–2.57 0.0004
Lower stable weight 1.06 0.82–1.37 0.666 1.05 0.80–1.37 0.736 1.05 0.80–1.38 0.710
Weight gain 1.35 0.96–1.90 0.088 1.47 1.03–2.09 0.0348 1.47 1.03–2.10 0.0347
Weight loss 1.00 — — 1.00 — — 1.00 — —
Age (years) — 1.02 1.01–1.03 0.0001 1.02 1.01–1.03 0.0008
Male sex 0.81 0.68–0.96 0.0169 0.81 0.68–0.97 0.0203
Blood pressure above goal (baseline)§ 3.02 2.45–3.73 0.0001 2.94 2.37–3.64 0.0001
Blood pressure medication class year 4
-blockers 0.88 0.73–1.07 0.193
Diuretics 1.05 0.86–1.29 0.609
ACE inhibitor/ARB 1.04 0.86–1.25 0.691
Other antihypertensives  1.33 1.05–1.69 0.0194
*A1Cmodelsincludethe1,911(74.2%)patientswhohadoneormoreA1Cmeasureinbothyears1and4;above-goalisA1C7%.†Bloodpressuremodelsinclude
the 2,409 (93.6%) patients that had one or more blood pressure measurement at both baseline and year 4; above-goal is 130/80 mmHg. ‡These subgroups also
contain23(1.2%)patientstakingathiazolidinedioneoracarboseduringyear4.Nopatientsweretakingrepaglinideduringyear4.§Baselinebloodpressurecontrol
based upon mean in 12-month pre-index of 130/80 mmHg.  Includes all remaining classes of medication used for hypertension. ARB, angiotensin receptor
blocker.
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tes medication use likely also affects
weight trajectories (21). The weight-loss
group had little change in metformin use
(often associated with weight loss) (21).
Thus, medication use patterns cannot ex-
plain the improved trajectory and A1C
patterns in the weight-loss group.
Ourstudyhasseverallimitations.The
study was conducted at one HMO in two
states, so ﬁndings may not be generaliz-
able to other settings. We studied only
survivors, so we do not know weight-
change patterns for everyone or how they
related to outcomes. However, our study
was strengthened by access to many mea-
sures taken in a large group of communi-
ty-based diabetes patients, including
diagnostic data that might suggest unin-
tentional weight change. Our data were
collected during clinical care; thus,
weight and other measurements may not
have been as precise or complete as they
wouldbeduringaclinicaltrial.Forexam-
ple, we did not have a true baseline A1C
on all patients and, instead, used year 1
ﬁndings. However, this was a conserva-
tive approach, and ﬁndings were largely
unchanged when analyses were restricted
to those with a baseline measure.
We did not evaluate possible mecha-
nisms that might explain the improved
A1Candbloodpressurecontrolobserved
in the weight-loss group. The lasting ben-
eﬁt, in spite of weight regain, may derive
from increased insulin sensitivity remain-
ing from weight loss (22); mechanisms
related to “metabolic memory” (23); life-
style changes accompanying weight loss,
such as improved diet or increased activ-
ity; or other unmeasured factors that dif-
fered among the weight-trajectory groups.
Wedidnotevaluatewhichbehaviorsledto
weight change. These areas should be the
focusoffutureresearch.Interestingly,the
strength of the trajectory method is high-
lighted by the ﬁnding that baseline BMI
alone did not signiﬁcantly predict above-
goal A1C in year 4.
We conclude that, in this analysis, a
weight-loss trajectory predicted im-
proved glycemic and blood pressure con-
trolwhencomparedwithstable-weightor
weight-gain trajectories. In light of previ-
ously reported positive effects of weight
loss on therapeutic outcomes in people
with diabetes (3,17,19) and our added
ﬁndings of the natural history of weight
lossandoutcomesindiabetesinthecom-
munity, more focus should be placed on
helpingcliniciansimplementprogramsto
manage weight trajectories in new dia-
betic patients.
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